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Abstract 
Abdominal aortic aneurysm (AAA) is a silent, progressive disease with high mortality and 
increasing prevalence with aging. Smooth muscle cell (SMC) dysfunction contributes to 
gradual dilatation and eventual rupture of the aorta. Here we studied phenotypic 
characteristics in SMC cultured from end-stage human AAA (5cm) and cells cultured from 
a porcine carotid artery (PCA) model of early and end-stage aneurysm.  
Human AAA-SMC presented a secretory phenotype and expressed elevated levels of 
differentiation marker miR-145 (2.2-fold, P<.001) and senescence marker SIRT-1 (1.3-fold, 
P<.05), features not recapitulated in aneurysmal PCA-SMC. Human and end-stage porcine 
aneurysmal cells were frequently multi-nucleated (3.9-fold, P<.001 and 1.8-fold, P<.01 
respectively, versus control cells) and displayed aberrant nuclear morphology. Human AAA-
SMC exhibited higher levels of the DNA damage marker H2AX (3.9-fold, P<.01 vs. control 
SMC). These features did not correlate with patients’ chronological age; and are therefore 
potential markers for pathological premature vascular aging. Early-stage PCA-SMC (control 
and aneurysmal) were indistinguishable from one another across all parameters. 
The principal limitation of human studies is tissue availability only at end-stage disease. 
Refinement of a porcine bioreactor model would facilitate study of temporal modulation of 
SMC behaviour during aneurysm development and potentially identify therapeutic targets to 
limit AAA progression. 
 
Key words: Abdominal aortic aneurysm; human; porcine; smooth muscle cells; aging; DNA 
damage; senescence; in vitro. 
Introduction  
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Abdominal aortic aneurysm (AAA) is a progressive, generally asymptomatic dilatation of the 
aorta affecting ~5.5% of the population. Risk factors for AAA include male gender, 
increasing age and smoking [1]. Rupture is associated with a high mortality risk of 60-70%; 
consequently, national screening programmes have been established to detect AAA in men 
over the age of 65 [1].  Elective open or endovascular repair is then offered when the risks of 
intervention are outweighed by the annual risk of rupture, which is correlated with AAA size.  
AAA is a multi-factorial disease. The pro-inflammatory infiltration of the aorta by immune 
cells such as macrophages and lymphocytes has been recognised for many years and has 
consequently been the focus of intensive research [2]. In addition to the inflammatory 
component, AAA is characterised by progressive decline in the number of smooth muscle 
cells (SMC) within the aortic wall [3], and degradation of extracellular matrix (ECM) through 
the production of matrix metalloproteinases (MMPs) [4]. In combination, this weakens the 
structural integrity of the aorta, rendering it more susceptible to rupture. 
SMC are the principal cellular component of the vascular wall and they play essential roles in 
maintaining vessel architecture and remodelling in response to environmental stimuli. They 
do this through switching between contractile (differentiated) and synthetic (dedifferentiated) 
phenotypes [5]. Whilst this plasticity is essential to adaptive remodelling, it is also implicated 
in the development of human AAA [6-9] and animal models of abdominal and thoracic 
aneurysm [6, 10]. Undeniably the involvement of SMC in AAA progression is an area worthy 
of research, however the key challenge facing investigators is that human tissue is accessible 
only at end-stage disease. Whilst animal models are undoubtedly of great value in AAA 
research, they do not fully recapitulate the clinical scenario in man as they are most 
commonly artificially induced via treatment with angiotensin II, calcium chloride or elastase, 
or mechanically induced using balloon angioplasty [11]. As such, they benefit from being 
complemented with alternative models. 
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SMC isolated from end-stage human tissue exhibit diverse features in culture [7-9]. Recently, 
we described a distinct SMC phenotype isolated from end-stage human AAA tissue (aortic 
diameter ≥5 cm) characterised by a large rhomboid morphology, slow proliferative rate, 
increased senescence and reduced levels of secreted MMP-2 compared to SMC cultured from 
non-aneurysmal human saphenous vein (SV) [9]. Furthermore, we established a novel ex vivo 
bioreactor model whereby porcine carotid arteries (PCA) were briefly treated with a 
combination of collagenase and elastase (CCE) or control vehicle gel (VEH), then maintained 
under flow for 12 days in a bioreactor. During this time, dilatation of the vessel was apparent 
and importantly, CCE-SMC derived from the vessels retrieved at the end of the culture period 
were compatible with those of end-stage human AAA-SMC with respect to morphology and 
behaviour in culture [9]. There is clearly a demand for models that may help identify factors 
that precede aneurysm development in order to find targets for new therapeutics.  
The risk of AAA increases with age [1], however the effects of aging on SMC are 
controversial with multiple conflicting reports regarding its influence on SMC proliferation, 
migration and inflammation (recently reviewed in [12]). Some of the phenotypic features of 
AAA-SMC that we have described, namely aberrant morphology, increased senescence and 
poor proliferative capacity [9] correspond to features apparent in aged SMC [13], however 
our observation of reduced MMP-2 secretion is at variance with animal models of aging [14]. 
Aging is associated with increased production of proinflammatory cytokines [15] and the 
development of cellular senescence, which has a multitude of effects on cell phenotype and 
behaviour [16]. We hypothesised that human AAA-SMC and porcine CCE-SMC would 
display features consistent with a premature aging phenotype. Consequently, the purpose of 
this study was to perform a detailed side-by-side comparison of human AAA-SMC and 
porcine CCE-SMC. Cells were explored in terms of morphology, expression of markers 
associated with aging and senescence (sirtuin-1, -3 and -6, miR-145), and evaluation of DNA 
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damage (H2AX). In a further series of experiments, we also examined these features in 
porcine cells cultured from vessels maintained in the bioreactor for a shorter interval (3 days) 
to explore the temporal nature of aneurysm pathology. 
 
Methods 
Human cell isolation  
Human SMC were isolated using an explant technique as previously described [17]. 
Aneurysmal (AAA) SMC were isolated from tissue fragments from patients undergoing open 
surgical repair, and non-aneurysmal SMC were isolated from SV or internal mammary artery 
(IMA) of patients undergoing coronary artery bypass grafting. Mean aneurysm diameter was 
6.48 ± 0.22 (range 4.9 - 9.5) cm. All procedures were performed at the Leeds General 
Infirmary. Approval of the experimental protocol was given by Leeds West Research Ethics 
Committee (ref CA/01/040) and all patients gave informed, written consent. The study 
conformed to the Declaration of Helsinki. Following explant, established SMC were 
maintained in Dulbeccos’s Modified Eagle Medium (DMEM) supplemented with 10% foetal 
calf serum (FCS), 1% L-Glutamine and 1% penicillin/streptomycin fungizone (full growth 
medium, FGM) at 37
o
C in 5% CO2 in air and serially passaged using trypsin/EDTA as 
necessary. All experiments were performed on cells between passages 3-6.  
Bioreactor and porcine cell isolation  
Porcine carotid arteries (PCA) were harvested from four month old, 65kg animals as 
previously described [9]. All procedures were performed according to UK Home Office 
regulations. Isolated vessels were treated with control gel (VEH) or gel containing 
collagenase and elastase (CCE), to induce an aneurysm-like dilatation of the vessel and 
maintained in a bioreactor under flow for 12 days (classified as 'end stage'), as previously 
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described [9] or 3 days (classified as 'early stage'). SMC were subsequently explanted from 
the retrieved vessels and maintained in FGM. As for human SMC, experiments were 
performed on early passage cells (3-6). 
Light microscopy 
Sub-confluent cells in FGM were imaged under phase at x100 magnification to examine any 
visible cytoskeletal and ultra-structural features. For quantification of multi-nucleation, 
multiple fields of view were acquired and the number of nuclei in ~150 individual cells were 
enumerated. Multi-nucleated cells were represented as a proportion of the total number of 
cells examined. 
Immunocytochemistry 
Cells were cultured on glass coverslips in FGM for 96h prior to fixation in 4% 
paraformaldehyde. The F-actin cytoskeleton was visualised using rhodamine phalloidin as 
previously described [18]. Both low (x200) and high magnification (x630) images were taken 
in multiple fields using a LSM510 Upright confocal microscope. 
To examine nuclear morphology, five random fields of view were imaged for each DAPI-
stained cell population at x400 magnification. Nuclei were classified as ‘normal’ (ovoid) or 
‘aberrant’ (irregular with blebbing, or apoptotic), and the proportion of aberrant nuclei 
calculated. To aid the distinction between the two classifications, DAPI was visualised in 
yellow to give a clear contrast. 
For quantification of H2AX-positive nuclei, cells were stained with primary H2AX 
antibody (1:100) overnight followed by Cy3-conjugated donkey anti-rabbit secondary 
antibody (1:400) for 3 h at room temperature before mounting using ProLong Gold 
containing DAPI nuclear stain. Five random fields of view were captured from each cell 
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population at x200 magnification. Data were expressed as the proportion of H2AX-positive 
nuclei (pink) relative to the total number of nuclei (blue and pink). 
RNA isolation and RT-PCR  
RNA was isolated from cells cultured in FGM and reverse transcribed as previously 
described [19]. Expression of SIRT-1, SIRT-3 and SIRT-6 in human and porcine cells was 
determined using specific TaqMan assays and expressed as a percentage of GAPDH. 
For miR-145, RNA was reverse transcribed as previously described [20] and expression of 
human and porcine miR-145 determined using specific TaqMan assays and expressed as a 
percentage of short ribonuclear RNA, U6. 
Statistical analyses 
Data are expressed as mean±SEM with n representing the number of experiments on cells 
from different patients or animals. Statistical analysis was performed using GraphPad Prism 
and ratio t-tests, one-way ANOVA with Newman-Keuls post-hoc test as appropriate. 
Correlative data was tested for normality using D’Agostino and Pearson omnibus test and any 
associations identified using Spearman or Pearson correlation as appropriate. Correlation 
between different factors is indicated by r. P<.05 was considered statistically significant. 
Results 
SMC morphology 
AAA-SMC frequently presented perinuclear granulation; a feature seldom observed in non-
aneurysmal SV or IMA-SMC (Fig. 1A). Most strikingly, AAA-SMC often exhibited a 
defined, fragmented cytoskeleton that was clearly visible under light microscopy (Fig. 1A). 
We examined the cytoskeleton in more detail using rhodamine phalloidin to stain F-actin 
fibres. Low magnification images (x200) were used to illustrate that staining was apparent in 
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all cells within the population, and high magnification images (x630) were obtained to 
visualise the organisation of F-actin fibres in greater detail. Substantial fragmentation was 
evident under both low and high power magnification in AAA-SMC, in contrast to long, 
parallel F-actin fibres that were visible in SV-SMC (Fig. 1B) and in IMA-SMC [21].  
As previously noted, porcine SMC were smaller than human SMC [9] making perinuclear 
granulation and the cytoskeleton more difficult to decipher using light microscopy, although 
they were visible to a degree. There was no apparent difference in granulation or cytoskeletal 
prominence in any early stage CCE-SMC (Fig. 1C), and F-actin fibres were maintained in an 
ordered configuration resembling those of VEH-SMC (Fig. 1D). In contrast, there was clear 
evidence of perinuclear granulation in end stage CCE-SMC and disruption to the 
cytoskeleton which was not evident in VEH-SMC (Fig. 1E); an observation that was 
exemplified using immunofluorescence (Fig. 1F).  
Senescence markers 
AAA-SMC expressed SIRT-1, -3 and -6, and had significantly lower expression of SIRT-1 
compared to SV-SMC but not IMA-SMC (Fig. 2A). SIRT-3 and SIRT-6 were not different 
between the groups. SIRT-6 expression levels were consistently lower than SIRT-1 and 
SIRT-3 regardless of SMC source (Fig. 2A).  
The reduced expression of SIRT-1 in AAA-SMC was not replicated in porcine SMC. In early 
stage CCE-SMC, SIRT-1 expression was comparable to VEH-SMC in two out of the three 
vessels studied, however the third vessel had a higher expression of SIRT-1 in the VEH-
SMC. This skewed the data yet, it still remains non-significant (P=.494, Fig. 2C). SIRT-3 
was also unaffected by CCE treatment (Fig. 2C). In end stage experiments, there were no 
significant differences between CCE-SMC and VEH-SMC (Fig. 2D). Expression of SIRT-1 
and SIRT-3 was routinely higher in porcine SMC (by 2.6- and 2.1-fold respectively) than in 
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human cells; although expression of SIRT-6 was undetectable in all porcine RNA samples 
(data not shown). 
Expression levels of miR-145 in AAA-SMC were >2-fold higher than in non-aneurysmal 
cells (57.4% vs. 26.0% in SV-SMC and 20.5% in IMA-SMC; Fig. 2B). However, we did not 
see this variance in porcine cells (neither early nor end stage) where overall expression levels 
were similar between all CCE- and VEH-SMC (Fig. 2E-F). 
Given that SV- and IMA-SMC were phenotypically comparable (Fig. 1, 2) we subsequently 
used SV-SMC as a non-aneurysmal comparator for the remainder of the study due to ready 
availability of primary tissue and consistency with our published report [9]. 
Markers of DNA damage 
AAA-SMC exhibited a higher frequency of multi-nucleation than SV-SMC, with 7.4% of 
cells containing two or more nuclei (Fig. 3A). In contrast, only 1.8% of SV-SMC were multi-
nucleated (Fig. 3A). AAA-SMC also had a greater proportion of aberrant nuclei (18.5%) 
compared to 7.6% in SV-SMC (Fig. 3B). Furthermore, 32.4% of AAA-SMC stained 
positively for H2AX compared with only 8.3% in SV-SMC (Fig. 3C). 
Early stage SMC demonstrated a modest elevation in the proportion of multi-nucleated cells 
compared with end stage cells, either human or porcine. However, there was no difference 
between VEH- versus CCE-SMC at this time point (Fig. 3D). Consistent with this, there were 
few aberrant nuclei in either group (Fig. 3E). In early stage experiments, H2AX positive 
nuclei were frequent although the degree of DNA damage was minor, as evidenced by few 
positive foci per nucleus (Fig. 3F).  
In contrast, there was divergent multi-nucleation and aberrant nuclei in end-stage porcine 
SMC which was significantly elevated in CCE-SMC (Fig.3G, H). There was a trend towards 
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a greater number of H2AX-positive nuclei in CCE-SMC, and these exhibited a higher degree 
of DNA damage with multiple foci (Fig. 3I).  
Association of experiments with age 
SMC were isolated from surgical samples acquired from a total of 31 patients undergoing 
AAA open repair (mean age 72.61.1 years, range 67-87 years, 93% male) and from the SV 
from a total of 57 patients harvested sequentially during coronary artery bypass grafting 
(mean age 62.61.5 years, range 40-83 years, 89% male; P<.001, Fig. 5A). 
In order to determine whether chronological patient age accounted for the differences we 
observed, we performed correlative analysis for chronological age in both the AAA and SV 
groups. Here, analysis was performed specifically on the subset of patient cells that were used 
for each particular experiment. Cells were selected for experimental use chronologically and 
not preselected according to clinical or cell behavioural data. This investigation revealed that 
patient donor age was not significantly correlated to SIRT-1 or miR-145 expression (Fig. 5B-
C), the number or morphology of nuclei (Fig. 5D-E) or the degree of H2AX positivity (Fig. 
5F). We propose that these features are therefore markers of pathological, vascular aging 
rather than attributable to the age of the patient donor. 
 
Discussion  
AAA disease is a significant healthcare problem with high mortality from rupture. The 
present study builds on our previous work demonstrating that end-stage AAA-SMC and 
porcine CCE-SMC are significantly larger than non-aneurysmal controls [9] and has revealed 
for the first time that SMC derived from both human end-stage AAA tissue and ex vivo 
protease-treated porcine arteries maintained under flow, exhibit features consistent with 
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premature aging and increased DNA damage. This could conceivably underlie, at least in 
part, their impaired functionality. 
The morphological characteristics of aneurysmal SMC (both human and end-stage CCE) 
were distinct, comprising a large spread cell area and rhomboid morphology [9]. Importantly, 
aberrant morphology was apparent in cells emerging early from primary explants (data not 
shown). All experiments in this study and in our previous report [9] were performed on early 
passage cells (p3-p6), an interval over which we have confirmed that morphological 
characteristics are retained [21]. In the current study, we have extended our morphological 
characterisation by noting marked aberrations in the F-actin cytoskeleton. Similar F-actin 
features – namely, truncated and disorganised fibres – have also been described in SV-SMC 
from patients with Type 2 diabetes (T2DM) [22, 20, 21]. As both aneurysm disease and 
T2DM are considered to be conditions characterised by premature aging [23, 24] it is feasible 
that disorganisation of F-actin in SMC is a feature of aged cells, rather than representative of 
a particular disease pathology per se. 
SMC are highly plastic and can switch between differentiated, contractile and 
dedifferentiated, synthetic phenotypes which is essential to their function [5]. The synthetic 
phenotype is characterised by morphological changes including adoption of a rhomboid 
appearance, myofilament loss and an increase in synthetic organelles including Golgi 
apparatus and rough endoplasmic reticulum [5]. Whilst we did not investigate markers of 
secretory organelles it is likely that the perinuclear granulation we observed in the human and 
end-stage porcine aneurysmal cells, in combination with aberrant cell morphology and 
disorganisation of the cytoskeleton, are indicative of a switch towards a secretory phenotype. 
It has been suggested that this could be an artefact caused by the in vitro nature of this study, 
and could have been induced due to differences in cell size or proliferative capacity that we 
have previously described [9]. AAA-SMC are undeniably larger than SV-SMC in culture and 
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have a slower proliferative rate [9], however their size and impaired proliferative capacity are 
comparable with our documented phenotypic characterisation of IMA-SMC [21]. In the 
present study, a substantially higher proportion of AAA-SMC exhibited ‘secretory’ features 
compared to IMA-SMC (Fig. 1A/B), asserting that our observations are not due to in vitro 
conditions but instead are related to their previous in vivo environment.    
Cells that permanently withdraw from the cell cycle adopt a senescence-associated secretory 
phenotype (SASP) characterised by secretion of various mediators, typically IL-1, IL-6, IL-8 
and monocyte chemoattractant protein (MCP)-1 [16]. These secreted factors can induce 
senescence in neighbouring cells via paracrine/autocrine mechanisms, a phenomenon known 
as a ‘bystander effect’ [25]. AAA-SMC exhibit telomere attrition [26] and we previously 
demonstrated that aneurysmal SMC exhibit a greater degree of senescence, indicated by β-
galactosidase staining [9]. We therefore examined the expression of sirtuins; longevity 
proteins whose expression is inversely correlated with cell age [27]. Indeed SIRT-1, via a 
p53-dependent mechanism, can promote DNA repair and regulate the cell cycle, thereby 
promoting viability and longevity [28]. Whilst lower expression levels of SIRT-1 in AAA-
SMC compared to non-aneurysmal SV-SMC supports our hypothesis of premature aging, this 
was not a feature replicated in the porcine model (either early or end-stage) nor in IMA-SMC, 
suggesting that SIRT-1 expression may be inherently variable between vascular beds. 
However, basal expression levels of SIRT-1 in porcine SMC were 2.6-4.9-fold higher than 
corresponding expression levels in human SMC, supporting the concept that the porcine cells 
were physiologically ‘younger’ than the end-stage human cells. In patients with AAA, 
dilation progresses over many years [29]. In order to induce a temporally aged porcine model 
that more accurately mirrors the human condition, it seems likely that culture in the 
bioreactor over an extended period is necessary, whilst providing conditions that are able to 
maintain vessel viability throughout. 
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MiR-145 is highly expressed in SMC and is involved in differentiation [24] and is reportedly 
dysregulated in a number of cardiovascular pathologies [21, 25]. miR-145 is an important 
regulator of vascular SMC phenotype, and we demonstrated its role in driving phenotypic 
change in human SV-SMC. Specifically, over-expression of miR-145 caused cells to become 
large and spread, disrupted the F-actin cytoskeleton, and reduced proliferation. This previous 
report also discovered elevated levels of miR-145 in native T2DM-SMC compared to non-
diabetic SV, which was maintained throughout serial passaging [20]. Importantly, this 
elevation was observed in age-matched patients which strengthens the notion that miR-145 is 
unlikely to be related to donor age. Our data presented here and previously [9] indicate that 
an enlarged, slowly proliferating cell phenotype is common to both AAA-SMC and T2DM-
SMC.  Here we observed elevated levels (2.2-fold) of miR-145 relative to venous and arterial 
non-aneurysmal SMC. Interestingly, expression of miR-145 is reportedly elevated in 
ascending aortic aneurysm tissue [30]. Increasing age is a key risk factor for the development 
of AAA, which is most prevalent in males over the age of 65 years [1], and premature 
vascular aging is also considered to underlie the development of cardiovascular 
complications in T2DM [31]. SV-SMC from T2DM patients express miR-145 at levels 
comparable to those described here in AAA-SMC [20]; it is therefore conceivable that miR-
145 serves as a marker of prematurely aged vascular SMC in general, and is not necessarily 
specific to a particular pathology. In the bioreactor, where the time course of vessel dilatation 
is accelerated, it is unlikely that porcine cells undergo a comparable sequential disease 
process following the application of CCE.  
A key driver of cellular aging is DNA damage, whereby cells temporarily withdraw from the 
cell cycle and undergo DNA repair to prevent mutations in future generations. When DNA 
damage is overwhelming to a degree that exceeds the capacity of the cell to undergo DNA 
repair, permanent withdrawal from the cell cycle and senescence or apoptosis ensues [32]. 
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Multi-nucleation and nuclear deformation are features of sustained DNA damage and aging 
[13, 27] and further, phosphorylation of histone H2AX (H2AX) is an early event in double-
stranded DNA damage signalling [28]. Our current and previous data demonstrate 
conclusively that aneurysmal SMC are senescent [9], therefore it was logical to explore any 
evidence of persistent DNA damage. We examined multi-nucleation (a feature of senescent 
and damaged cells [33, 34]), deformation of normal ovoid nuclear morphology (more 
common in aged and DNA damaged cells [35, 13]) and the presence of H2AX (an early 
event in double-stranded DNA damage [36]). Our results show unequivocally that human 
AAA-SMC exhibit a greater extent of DNA damage than non-aneurysmal SMC, in 
agreement with a previous study that also examined H2AX and 8-dihydro-8-oxo-2'-
deoxyguanosine as a marker of oxidative DNA damage [26]. However, in that study AAA-
SMC were explored in situ in tissue sections, or isolated as primary cells by a cytospin 
method without culturing [26]. It is notable that in early-stage PCA-SMC, the presence of 
multi-nucleation was high in both VEH- and CCE-SMC alike. This was paralleled by a 
higher proportion of H2AX-positive cells in both groups, however these cells exhibited  few 
foci in each nucleus compared with  either human or porcine end stage aneurysmal cells (Fig. 
3C, F, I). It could be argued that the procedure of preparing and placing vessels in the 
bioreactor induces transient and reversible DNA damage although this would require 
additional corroboration. 
Persistence of DNA damage throughout culture and passaging is likely explained by the 
existence of epigenetic mechanisms. A number of microRNAs are known to regulate proteins 
involved in the DNA damage response pathway, for example miR-421 (targets ATM), miR-
24 (targets H2AX) and miR-125b (targets p53). Furthermore, activation of the DNA damage 
response up-regulates transcription and processing of a further subset of miRs including miR-
34, miR-145 and miR-215 (reviewed in [37]). In the present study we observed persistent 
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DNA damage in porcine cells without elevated levels of miR-145, therefore it is unlikely that 
miR-145 is a causative factor of the DNA damage we observe in both human and porcine 
aneurysmal SMC. miR-24 reportedly inhibits SMC proliferation [38] and miR-34 is up-
regulated in senescent SMC [39]; these are worthy of investigation and may represent 
promising candidates for future research.  
In summary, our data support the notion that end-stage aneurysmal SMC (both human and 
porcine) exhibit characteristics consistent with DNA damage and a senescence associated 
secretory phenotype. These features are not present in early-stage porcine SMC, suggesting 
that they are imparted later in the temporal progression of aneurysm development. Identifying 
the critical time point where DNA damage can first be detected may provide opportunities to 
develop interventions which could prevent or even reverse this damage. In this respect, 
application of a further interim time point in the bioreactor could provide an opportunity for 
evaluating potential therapeutic agents, introduced early and evaluated for efficacy at the later 
times. In the longer term, these data may lead to development of new pharmacological 
interventions for AAA in man. 
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Figure 1: Morphological features of aneurysmal SMC. Sub-confluent cells were cultured 
in full growth medium and imaged at x100 magnification. (A) AAA-SMC commonly 
exhibited granulation in the perinuclear region and often had a cytoskeleton that was visible 
under phase (arrows). SV-SMC and IMA-SMC did not exhibit these features. Representative 
images, with the previously described difference in cell size clearly evident [9]. Scale bar = 
100 μm. (B) Cells were fixed and stained with rhodamine phalloidin to visualise the F-actin 
cytoskeleton (red). Nuclei were stained blue with DAPI. Truncated and disorganised F-actin 
filaments were apparent under both low (x200) and high (x630) magnification, whereas SV-
SMC fibres were elongated and traversed the cells. Upper panel scale bar = 100 μm, lower 
panel scale bar = 20 μm. (C) and (D) The same analyses were performed on VEH-SMC and 
CCE-SMC from porcine carotid arteries maintained for 3 days in the bioreactor (‘early 
stage’). Granulation and aberrant cytoskeletal features were very infrequent under any 
conditions. (E) and (F) Conversely, perinuclear granulation and truncation of the F-actin 
cytoskeleton was readily visible in CCE-SMC from 12 day bioreactor experiments (‘end 
stage’) compared to VEH-SMC. 
Figure 2: Expression of markers related to DNA damage and senescence. SMC were 
cultured for 4 days in full growth media and RNA isolated. (A) Expression of SIRT-1, SIRT-
3 and SIRT-6, all of which are known to decline in senescent cells (n=10, *P<.05, ns=non-
significant vs. SV-SMC). (B) Expression of miR-145, a microRNA involved with DNA 
damage and that we have previously shown to be up regulated in senescent SMC from 
patients with type 2 diabetes [20] (n=12, ***P<.001 vs. SV-SMC or IMA-SMC). (C) and (D) 
In ‘early’ or ‘end-stage’ experiments, there was no difference in SIRT-1 or SIRT-3 
expression amongst any conditions. SIRT-6 was not detected in porcine cells (n=3). (E) and 
(F) Expression of miR-145 was not affected by CCE in either ‘early’ or ‘end-stage’ 
experiments (n=3), in contrast to the increase seen in AAA-SMC. 
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Figure 3: Aneurysmal SMC display features of DNA damage. Sub-confluent cells were 
cultured in full growth medium and their nuclear morphology analysed. (A) The proportion 
of multi-nucleated cells in ~100 cells per patient were quantified (n=20, ***P<.001 vs. SV-
SMC). Lower panel = representative images from AAA-SMC and SV-SMC with number of 
nuclei per cell indicated, scale bar = 100 μm. (B) Cells were fixed and the proportion of 
aberrant nuclei in ~100 cells per patient counted (n=6, *P<.05 vs. SV-SMC). Lower panel = 
representative images from AAA-SMC and SV-SMC, scale bar = 50 μm. Nuclei are stained 
with DAPI (yellow). Aberrant nuclei are denoted by an asterisk. (C) Cells were fixed and the 
proportion of ~150 cells per patient exhibiting double stranded DNA damage was quantified 
(n=6, ***P<.01 vs. SV-SMC). Lower panel = representative images from AAA-SMC and 
SV-SMC, scale bar = 100 μm. DNA damage positive nuclei counterstain pink through co-
localisation of H2AX (red) and DAPI (blue). (D-F) Identical experiments were performed 
on control and enzyme-treated porcine SMC from ‘early-stage’ experiments for (D) multi-
nucleation (n=3, ns = non-significant vs. VEH-SMC), (E) nuclear morphology (n=3, ns = 
non-significant vs. VEH-SMC) and (F) H2AX-positive nuclei (n=3, ns=non-significant vs. 
VEH-SMC). (G-I) Identical experiments were performed on control and enzyme-treated 
porcine SMC from ‘end-stage’ experiments for (G) multi-nucleation (n=3, **P<.01 vs. VEH-
SMC), (H) nuclear morphology (n=3, *P<.05 vs. VEH-SMC) and (I) H2AX-positive nuclei 
(n=3, ns=non-significant vs. VEH-SMC). 
Figure 4: Correlation of chronological age with features associated with pathological 
premature ageing. (A) Age of patients whose SMC were used in this study (AAA-SMC 
n=31, SV-SMC n=57, ***P<.001). (B-F) Correlations of chronological age with markers of a 
pathological premature ageing phenotype in both AAA- and SV-SMC (B) SIRT-1, (C) miR-
145, (D) multi-nucleation, (E) aberrant nuclear morphology, (F) H2AX-positive nuclei. Data 
were tested for normality using D’Agostino & Pearson omnibus normality test followed by 
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Pearson or Spearman correlation analysis as appropriate. r refers to the correlation between 
the two factors. All P values non-significant. 
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